IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Average Rating of “Moderate Buy” by Analysts

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) has been assigned a consensus recommendation of “Moderate Buy” from the eighteen brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and fourteen have issued a buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $43.3571.

Several equities research analysts have recently issued reports on IDYA shares. Guggenheim started coverage on IDEAYA Biosciences in a research report on Thursday, September 18th. They set a “buy” rating and a $50.00 target price for the company. TD Cowen initiated coverage on IDEAYA Biosciences in a report on Tuesday, July 22nd. They issued a “buy” rating for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of IDEAYA Biosciences in a report on Wednesday, October 8th. Royal Bank Of Canada lifted their price objective on IDEAYA Biosciences from $36.00 to $38.00 and gave the stock an “outperform” rating in a report on Tuesday, September 9th. Finally, Citizens Jmp initiated coverage on IDEAYA Biosciences in a report on Thursday, September 4th. They issued a “mkt outperform” rating and a $41.00 price objective for the company.

IDEAYA Biosciences Price Performance

Shares of IDEAYA Biosciences stock opened at $29.26 on Friday. IDEAYA Biosciences has a 1 year low of $13.45 and a 1 year high of $32.67. The firm has a market cap of $2.56 billion, a PE ratio of -7.72 and a beta of 0.14. The stock has a fifty day moving average price of $25.67 and a 200-day moving average price of $22.20.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its earnings results on Tuesday, August 5th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.03). The firm had revenue of $6.00 million during the quarter, compared to analysts’ expectations of $3.48 million. During the same period in the previous year, the company posted ($0.68) earnings per share. IDEAYA Biosciences’s revenue was up NaN% on a year-over-year basis. As a group, equities analysts anticipate that IDEAYA Biosciences will post -3.07 EPS for the current fiscal year.

Institutional Investors Weigh In On IDEAYA Biosciences

Large investors have recently added to or reduced their stakes in the company. Oppenheimer Asset Management Inc. increased its holdings in IDEAYA Biosciences by 33.2% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 11,560 shares of the company’s stock worth $189,000 after acquiring an additional 2,884 shares during the last quarter. American Century Companies Inc. purchased a new position in IDEAYA Biosciences during the 1st quarter valued at about $195,000. Palumbo Wealth Management LLC grew its holdings in IDEAYA Biosciences by 65.8% during the 1st quarter. Palumbo Wealth Management LLC now owns 22,402 shares of the company’s stock valued at $367,000 after buying an additional 8,893 shares in the last quarter. Swiss National Bank grew its holdings in IDEAYA Biosciences by 0.8% during the 1st quarter. Swiss National Bank now owns 150,800 shares of the company’s stock valued at $2,470,000 after buying an additional 1,200 shares in the last quarter. Finally, Signaturefd LLC grew its holdings in IDEAYA Biosciences by 58.1% during the 2nd quarter. Signaturefd LLC now owns 4,549 shares of the company’s stock valued at $96,000 after buying an additional 1,672 shares in the last quarter. Hedge funds and other institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.